National database for patients with primary sclerosing cholangitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a national database for patients diagnosed with primary sclerosing cholangitis (PSC) in Italy, a rare and chronic liver disease. The study will collect clinical information and link it to a biological sample storage to better understand the disease's epidemiology and impact. PSC is associated with significant health risks, including liver failure and cancer, and the database will help in assessing the true burden of the disease in the Italian population. By gathering comprehensive data, the study seeks to improve patient outcomes and inform future research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing and able to give informed consent prior to any study specific procedure being performed;
* Diagnosis of PSC according to the most recent published guidelines (EASL);

Exclusion Criteria:

* Subject unwilling to participate at the study

Where it's running

• ASST Monza
  Monza, Italy Recruiting
• Ospedali riuniti di Ancona
  Ancona, Italy Not yet recruiting
• Policlinico di Bari
  Bari, Italy Not yet recruiting
• ASST Bergamo ovest
  Bergamo, Italy Not yet recruiting
• ASST Papa Giovanni XXIII
  Bergamo, Italy Not yet recruiting
• Ospedale Sant'Orsola Malpighi
  Bologna, Italy Not yet recruiting

+13 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Pietro Invernizzi, MD
• Email: pietro.invernizzi@unimib.it
• Phone: 039 233 2187

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Elafibranor for adults with primary sclerosing cholangitis

  This trial will see if taking elafibranor once daily helps adults with primary sclerosing cholangitis compared with a placebo.

  Recruiting at 41 sites Phase 3 Ipsen · Chandler, Arizona and 230 other locations · NCT07387549

• TAK-781 treatment in healthy adults and people with non-cirrhotic primary sclerosing cholangitis

  This study will test whether TAK-781 is safe and tolerable in healthy adults and in people with non-cirrhotic primary sclerosing cholangitis while measuring how the body handles and responds to the drug.

  Recruiting Phase 1 Takeda · Salt Lake City, Utah · NCT07229911

• Preventing recurrence of primary sclerosing cholangitis after liver transplantation

  This study is testing if a daily medication called fenofibrate can help prevent primary sclerosing cholangitis from coming back in people who have had a liver transplant.

  Recruiting Phase 2 Mayo Clinic · Scottsdale, Arizona · NCT06905054

• LEOPARD: Predicting liver transplant dropout with AI in European patients

  This project tests new AI-based models to predict which liver transplant candidates are at highest risk of dropout or death while on the waitlist.

  Recruiting at 4 sites Assistance Publique - Hôpitaux de Paris · Ghent, Belgium and 7 other locations · NCT06723275

• Collecting data to improve liver transplantation predictions

  This study is trying to use AI to better predict which liver transplant candidates are at risk of dropping out of the waitlist, so that more people can get fair access to transplants across Europe.

  Recruiting at 53 sites Assistance Publique - Hôpitaux de Paris · Vienna and 52 other locations · NCT06675604

• Identifying liver disease-specific gut microbiomes

  This study is trying to find out if certain gut bacteria are linked to chronic liver diseases in adults, including autoimmune hepatitis and primary biliary cholangitis, by analyzing blood and stool samples from patients and their household members.

  Recruiting Chungnam National University Hospital · Daejeon, Jung-gu · NCT06519162

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.